A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)

This study is comparing two immunotherapy combinations in people newly diagnosed with advanced kidney cancer (metastatic renal cell carcinoma): nivolumab + ipilimumab (the current standard dual immunotherapy) versus a three-drug combination that adds relatlimab (which blocks a different immune checkpoint called LAG-3) to see if the triple combination works better. **You may be eligible if...** - You are 18 or older - You have confirmed clear cell kidney cancer that has spread to other parts of the body (Stage IV) - You have not received any prior systemic therapy for this kidney cancer - You have at least one measurable tumor - You are in good functional condition (Karnofsky score ≥70%) - Your organ function is adequate **You may NOT be eligible if...** - You have already received systemic treatment for kidney cancer - You have received prior neoadjuvant or adjuvant immunotherapy - You have conditions making immunotherapy unsafe Talk to your doctor to see if this trial is right for you.